RNN New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, And Cisplatin

Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.